The mammalian cell lines that are engineered to produce high-value recombinant-protein drugs also produce unwanted proteins that push up the overall cost to manufacture these drugs. These same proteins can also lower drug quality. In a new paper in Nature Communications, researchers have shown that their genome-editing techniques could eliminate up to 70 percent of the contaminating protein by mass in recombinant-protein drugs produced by the workhorses of mammalian cells — Chinese Hamster Ovary (CHO) cells.
- ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
- No benefit for post-operative radiotherapy in non-small-cell lung cancer
- First new drug in years reduces recurrence in high risk HR+ early breast cancer
- New first-line treatment option for metastatic kidney cancer
- UC study sheds light on cancer treatment, COVID-19